Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Ashish Sarraju; JingWei Li; Christopher P. Cannon; Tara Chang; Rajiv Agarwal; George Bakris; David M. Charytan; Dick de Zeeuw; Tom Greene; Hiddo J. L. Heerspink; Adeera Levin; Bruce Neal; Carol Pollock; David C. Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Vlado Perkovic; Meg Jardine; Kenneth W. Mahaffey

doi:10.1016/j.ahj.2020.12.008

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Ashish Sarraju, JingWei Li, Christopher P. Cannon, Tara Chang, Rajiv Agarwal, George Bakris, David M. Charytan, Dick de Zeeuw, Tom Greene, Hiddo J. L. Heerspink, Adeera Levin, Bruce Neal, Carol Pollock, David C. Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Vlado Perkovic, Meg Jardine, Kenneth W. Mahaffey^*

^*Corresponding author voor dit werk

Onderzoeksoutput › Academic › peer review

39 Citaten (Scopus)

66 Downloads (Pure)

Samenvatting

We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P <.001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure.

Originele taal-2	English
Pagina's (van-tot)	141-148
Aantal pagina's	8
Tijdschrift	American Heart Journal
Volume	233
DOI's	https://doi.org/10.1016/j.ahj.2020.12.008
Status	Published - mrt.-2021

Toegang tot document

10.1016/j.ahj.2020.12.008

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure_ Results from the CREDENCE trialFinal publisher's version, 3,31 MBLicentie: Taverne

Handle.net

Permanente koppeling

Vingerafdruk

Duik in de onderzoeksthema's van 'Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial'. Samen vormen ze een unieke vingerafdruk.

Citeer dit

Sarraju, A., Li, J., Cannon, C. P., Chang, T., Agarwal, R., Bakris, G., Charytan, D. M., de Zeeuw, D., Greene, T., Heerspink, H. J. L., Levin, A., Neal, B., Pollock, C., Wheeler, D. C., Yavin, Y., Zhang, H., Zinman, B., Perkovic, V., Jardine, M., & Mahaffey, K. W. (2021). Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 233, 141-148. https://doi.org/10.1016/j.ahj.2020.12.008

@article{70b358bef6cf4baf9bc55e16dfffffb7,

title = "Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial",

abstract = "We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P <.001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure.",

author = "Ashish Sarraju and JingWei Li and Cannon, {Christopher P.} and Tara Chang and Rajiv Agarwal and George Bakris and Charytan, {David M.} and {de Zeeuw}, Dick and Tom Greene and Heerspink, {Hiddo J. L.} and Adeera Levin and Bruce Neal and Carol Pollock and Wheeler, {David C.} and Yshai Yavin and Hong Zhang and Bernard Zinman and Vlado Perkovic and Meg Jardine and Mahaffey, {Kenneth W.}",

year = "2021",

month = mar,

doi = "10.1016/j.ahj.2020.12.008",

language = "English",

volume = "233",

pages = "141--148",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "MOSBY-ELSEVIER",

}

Sarraju, A, Li, J, Cannon, CP, Chang, T, Agarwal, R, Bakris, G, Charytan, DM, de Zeeuw, D, Greene, T, Heerspink, HJL, Levin, A, Neal, B, Pollock, C, Wheeler, DC, Yavin, Y, Zhang, H, Zinman, B, Perkovic, V, Jardine, M & Mahaffey, KW 2021, 'Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial', American Heart Journal, vol. 233, blz. 141-148. https://doi.org/10.1016/j.ahj.2020.12.008

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. / Sarraju, Ashish; Li, JingWei; Cannon, Christopher P. et al.
In: American Heart Journal, Vol. 233, 03.2021, blz. 141-148.

Onderzoeksoutput › Academic › peer review

TY - JOUR

T1 - Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure

T2 - Results from the CREDENCE trial

AU - Sarraju, Ashish

AU - Li, JingWei

AU - Cannon, Christopher P.

AU - Chang, Tara

AU - Agarwal, Rajiv

AU - Bakris, George

AU - Charytan, David M.

AU - de Zeeuw, Dick

AU - Greene, Tom

AU - Heerspink, Hiddo J. L.

AU - Levin, Adeera

AU - Neal, Bruce

AU - Pollock, Carol

AU - Wheeler, David C.

AU - Yavin, Yshai

AU - Zhang, Hong

AU - Zinman, Bernard

AU - Perkovic, Vlado

AU - Jardine, Meg

AU - Mahaffey, Kenneth W.

PY - 2021/3

Y1 - 2021/3

N2 - We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P <.001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure.

AB - We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P <.001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure.

U2 - 10.1016/j.ahj.2020.12.008

DO - 10.1016/j.ahj.2020.12.008

M3 - Article

C2 - 33358942

SN - 0002-8703

VL - 233

SP - 141

EP - 148

JO - American Heart Journal

JF - American Heart Journal

ER -